Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 423

1.

A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.

Ryan CJ, Harzstark AH, Rosenberg J, Lin A, Claros C, Goldfine ID, Kerner JF, Small EJ, Youngren JF.

BJU Int. 2008 Feb;101(4):436-9. doi: 10.1111/j.1464-410X.2007.07330.x. Erratum in: BJU Int. 2008 Jun;101(11):1483. Youngren, Jack F [added].

PMID:
18234062
[PubMed - indexed for MEDLINE]
2.
3.

A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer.

Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin AM, Fong L, Ryan CJ.

Oncol Rep. 2012 Jan;27(1):3-9. doi: 10.3892/or.2011.1487. Epub 2011 Oct 4.

PMID:
21971890
[PubMed - indexed for MEDLINE]
4.

A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.

Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ.

BJU Int. 2006 Oct;98(4):763-9.

PMID:
16796694
[PubMed - indexed for MEDLINE]
5.

Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.

Pathak AS, Pacificar JS, Shapiro CE, Williams SG.

J Urol. 2007 Jun;177(6):2132-5; discussion 2135.

PMID:
17509298
[PubMed - indexed for MEDLINE]
6.

Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.

Koutsilieris M, Mitsiades CS, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C, Tsintavis A.

Clin Cancer Res. 2004 Jul 1;10(13):4398-405.

PMID:
15240528
[PubMed - indexed for MEDLINE]
Free Article
7.

Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.

Pruthi RS, Derksen JE, Moore D, Carson CC, Grigson G, Watkins C, Wallen E.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2172-7.

PMID:
16609031
[PubMed - indexed for MEDLINE]
Free Article
8.

Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.

Sartor O, Gomella LG, Gagnier P, Melich K, Dann R.

Can J Urol. 2009 Oct;16(5):4806-12.

PMID:
19796455
[PubMed - indexed for MEDLINE]
9.

Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.

Beinart G, Rini BI, Weinberg V, Small EJ.

Clin Prostate Cancer. 2005 Jun;4(1):55-60.

PMID:
15992463
[PubMed - indexed for MEDLINE]
10.

Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells.

Ryan CJ, Zavodovskaya M, Youngren JF, Campbell M, Diamond M, Jones J, Shiry L, Allan G, Maddux BA, Goldfine ID.

Prostate. 2008 Aug 1;68(11):1232-40. doi: 10.1002/pros.20789.

PMID:
18491370
[PubMed - indexed for MEDLINE]
11.
12.

Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy.

Clark PE, Hall MC, Borden LS Jr, Miller AA, Hu JJ, Lee WR, Stindt D, D'Agostino R Jr, Lovato J, Harmon M, Torti FM.

Urology. 2006 Jun;67(6):1257-61.

PMID:
16765186
[PubMed - indexed for MEDLINE]
13.

Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy.

Barqawi AB, Moul JW, Ziada A, Handel L, Crawford ED.

Urology. 2003 Nov;62(5):872-6.

PMID:
14624911
[PubMed - indexed for MEDLINE]
14.

Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.

Tyrrell CJ, Iversen P, Tammela T, Anderson J, Björk T, Kaisary AV, Morris T.

BJU Int. 2006 Sep;98(3):563-72. Epub 2006 Jun 8. Erratum in: BJU Int. 2006 Sep;98(3):572.

PMID:
16771791
[PubMed - indexed for MEDLINE]
15.

A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.

Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP.

BJU Int. 2008 May;101(9):1084-9. doi: 10.1111/j.1464-410X.2008.07509.x.

PMID:
18399827
[PubMed - indexed for MEDLINE]
16.

High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma.

Beer TM, Lemmon D, Lowe BA, Henner WD.

Cancer. 2003 Mar 1;97(5):1217-24.

PMID:
12599228
[PubMed - indexed for MEDLINE]
Free Article
18.

Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma.

DiPaola RS, Chenven ES, Shih WJ, Lin Y, Amenta P, Goodin S, Shumate A, Capanna T, Cardiella M, Cummings KB, Aisner J, Todd MB.

Cancer. 2001 Oct 15;92(8):2065-71.

PMID:
11596021
[PubMed - indexed for MEDLINE]
19.

Role of estrogens in the secondary hormonal manipulation of hormone refractory prostate cancer.

Siddiqui K, Abbas F, Biyabani SR, Ather MH, Talati J.

J Pak Med Assoc. 2004 Sep;54(9):445-7.

PMID:
15518364
[PubMed - indexed for MEDLINE]
20.

Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone.

Morioka M, Kobayashi T, Furukawa Y, Jo Y, Shinkai M, Matsuki T, Yamamoto T, Tanaka H.

Urol Int. 2002;68(1):10-5.

PMID:
11803262
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk